StockData
Aligos Therapeutics, Inc. logo

Aligos Therapeutics, Inc. (ALGS) stock

ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3053% below fair value
$1.36−0.30 (-18.07%)

Close on Nov 17, 2026Market cap $16.99MP/E –Yield –

Aligos Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Aligos Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$78.99M. For fiscal 2025 it was -$87.99M. The highest annual figure on record is -$54.04M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$87.99M–
FY2024Dec 31, 2024-$89.15M–
FY2023Dec 31, 2023-$88.13M–
FY2022Dec 31, 2022-$97.58M–
FY2021Dec 31, 2021-$128.32M–
FY2020Dec 31, 2020-$97.83M–
FY2019Dec 31, 2019-$54.04M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.89M–
Q1 FY2026Mar 31, 2026-$26.93M–
Q4 FY2025Dec 31, 2025-$21.81M–
Q3 FY2025Sep 30, 2025-$28.36M–
Q2 FY2025Jun 30, 2025-$18.57M–
Q1 FY2025Mar 31, 2025-$19.24M–
Q4 FY2024Dec 31, 2024-$20.56M–
Q3 FY2024Sep 30, 2024-$20.13M–
Q2 FY2024Jun 30, 2024-$26.41M–
Q1 FY2024Mar 31, 2024-$22.05M–
Q4 FY2023Dec 31, 2023-$26.00M–
Q3 FY2023Sep 30, 2023-$19.07M–
Q2 FY2023Jun 30, 2023-$19.14M–
Q1 FY2023Mar 31, 2023-$23.92M–
Q4 FY2022Dec 31, 2022-$22.68M–
Q3 FY2022Sep 30, 2022-$18.95M–
Q2 FY2022Jun 30, 2022-$20.39M–
Q1 FY2022Mar 31, 2022-$35.56M–
Q4 FY2021Dec 31, 2021-$37.95M–
Q3 FY2021Sep 30, 2021-$33.07M–
Q2 FY2021Jun 30, 2021-$29.57M–
Q1 FY2021Mar 31, 2021-$27.74M–
Q4 FY2020Dec 31, 2020-$34.29M–
Q3 FY2020Sep 30, 2020-$21.56M–
Q2 FY2020Jun 30, 2020-$21.27M–
Q1 FY2020Mar 31, 2020-$20.72M–
Q4 FY2019Dec 31, 2019-$18.44M–
Q3 FY2019Sep 30, 2019-$14.50M–

More Aligos Therapeutics figures

See a number that looks wrong?